NCT00056290
Completed
Phase 1
p.VGI.1 (VEGF2) Gene Transfer for Diabetic Neuropathy
Losordo, Douglas, M.D.2 sites in 1 country60 target enrollmentDecember 2002
ConditionsDiabetic Neuropathy
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic Neuropathy
- Sponsor
- Losordo, Douglas, M.D.
- Enrollment
- 60
- Locations
- 2
- Primary Endpoint
- Safety
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
This gene therapy study is being conducted to evaluate intramuscular gene transfer using VEGF (Vascular Endothelial Growth Factor) in patients with diabetic neuropathy in the legs. This condition causes a decrease in feeling and sensation due to diabetes. VEGF is DNA, or genetic material that is injected into the muscles of the leg. Once in the leg, it has been shown to cause new blood vessels to grow under a variety of conditions.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Safety
Time Frame: 6 months
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
VEGF Gene Transfer for Critical Limb IschemiaCritical Limb IschemiaIschemiaLeg UlcerNCT00304837Losordo, Douglas, M.D.
Completed
Phase 1
rAAVrh74.MHCK7.DYSF.DV for Treatment of DysferlinopathiesDysferlinopathyNCT02710500Sarepta Therapeutics, Inc.2
Active, not recruiting
Phase 2
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)Sickle Cell DiseaseNCT05353647David Williams25
Recruiting
Phase 1
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisLysosomal DiseasesGangliosidosisGM1NCT03952637National Human Genome Research Institute (NHGRI)54
Completed
Phase 1
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body MyositisBecker Muscular DystrophySporadic Inclusion Body MyositisNCT01519349Nationwide Children's Hospital15